Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae | Zendy

Sidharth Chopra | Zendy; Kiminori Matsuyama | Zendy; Christina L. Hutson | Zendy; Peter B. Madrid | Zendy

Open Access

Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae

Author(s) -

Sidharth Chopra,

Kiminori Matsuyama,

Christina L. Hutson,

Peter B. Madrid

Publication year - 2011

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkr154

Subject(s) - mycobacterium chelonae , mycobacterium abscessus , antimicrobial , microbiology and biotechnology , mycobacterium , medicine , identification (biology) , biology , tuberculosis , pathology , botany

Rapidly growing mycobacteria have long been neglected in drug discovery efforts and this neglect is reflected in the paucity of therapeutic options available for diseases resulting from these infections. The purpose of this work is to identify new candidate drugs for treating non-tuberculous mycobacteria (NTM) by testing FDA-approved drugs for antimicrobial activity against Mycobacterium abscessus and Mycobacterium chelonae, two emerging NTM drug-resistant pathogens.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research